Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1982;41(Suppl 1):1–60. doi: 10.1136/ard.41.suppl_1.1-a

Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

PMCID: PMC1030282  PMID: 7065738

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexson E., Brandt K. D. Acute leukemia after azathioprine treatment of connective tissue disease. Am J Med Sci. 1977 May-Jun;273(3):335–340. [PubMed] [Google Scholar]
  2. Alpert M. E., Uriel J., de Nechaud B. Alpha-1 fetoglobulin in the diagnosis of human hepatoma. N Engl J Med. 1968 May 2;278(18):984–986. doi: 10.1056/NEJM196805022781804. [DOI] [PubMed] [Google Scholar]
  3. Anderson L. G., Talal N. The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol. 1972 Feb;10(2):199–221. [PMC free article] [PubMed] [Google Scholar]
  4. Apostoloff E., Reitzig P., Jendrusch C., Apostoloff G. Erfahrungen bei langzeitiger immunsuppressiver Therapie der Bindegewebskrankheiten. Z Gesamte Inn Med. 1974 Jan 1;29(1):26–30. [PubMed] [Google Scholar]
  5. Badley E. M., Ball J., Wood P. H. Proceedings: Interpreting the biological significance of rheumatoid factor. Ann Rheum Dis. 1975 Oct;34(5):463–463. doi: 10.1136/ard.34.5.463-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Balken W. J. Zur Therapie der progredient chronischen Polyarthritis. Klinische Untersuchung über die Wirksamkeit von Azathioprin. Fortschr Med. 1976 Sep 23;94(27):1504–1506. [PubMed] [Google Scholar]
  7. Barnikol H. U., Vorlaender K. O. Voraussetzungen und erste Ergebnisse zur therapeutischen Anwendung des Azathioprin (Imuran) beim chronisch-progredienten Gelenkrheumatismus und bei sogenannten Kollagenkrankheiten. Med Welt. 1967 Jan 21;3:160–169. [PubMed] [Google Scholar]
  8. Batchelor J. R., Welsh K. I., Tinoco R. M., Dollery C. T., Hughes G. R., Bernstein R., Ryan P., Naish P. F., Aber G. M., Bing R. F. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet. 1980 May 24;1(8178):1107–1109. doi: 10.1016/s0140-6736(80)91554-8. [DOI] [PubMed] [Google Scholar]
  9. Bennett J. C. The infectious etiology of rheumatoid arthritis. New considerations. Arthritis Rheum. 1978 Jun;21(5):531–538. doi: 10.1002/art.1780210507. [DOI] [PubMed] [Google Scholar]
  10. Berry H., Liyanage S. P., Durance R. A., Barnes C. G., Berger L. A., Evans S. Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial. Br Med J. 1976 May 1;1(6017):1052–1054. doi: 10.1136/bmj.1.6017.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brinkley J. R., Jr, Dubois E. L., Ryan S. J. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol. 1979 Jul;88(1):1–11. doi: 10.1016/0002-9394(79)90743-8. [DOI] [PubMed] [Google Scholar]
  12. Buriot D., Prieur A. M., Lebranchu Y., Messerschmitt J., Griscelli C. Leucémie aiguë chez trois enfants atteints d'arthrite chronique juvénile traités par le chlorambucil. Arch Fr Pediatr. 1979 Jun;36(6):592–598. [PubMed] [Google Scholar]
  13. CAMMARATA R. J., RODNAN G. P., JENSEN W. N. Systemic rheumatic disease and malignant lymphoma. Arch Intern Med. 1963 Mar;111:330–337. doi: 10.1001/archinte.1963.03620270056009. [DOI] [PubMed] [Google Scholar]
  14. COBB S., ANDERSON F., BAUER W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953 Oct 1;249(14):553–556. doi: 10.1056/NEJM195310012491402. [DOI] [PubMed] [Google Scholar]
  15. Cade R., Stein G., Pickering M., Schlein E., Spooner G. Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med J. 1976 Apr;69(4):388–392. doi: 10.1097/00007611-197604000-00003. [DOI] [PubMed] [Google Scholar]
  16. Calabro J. J. Cancer and arthritis. Arthritis Rheum. 1967 Dec;10(6):553–567. doi: 10.1002/art.1780100608. [DOI] [PubMed] [Google Scholar]
  17. Caldwell D. S. Musculoskeletal syndromes associated with malignancy. Semin Arthritis Rheum. 1981 Feb;10(3):198–223. doi: 10.1016/s0049-0172(81)80003-0. [DOI] [PubMed] [Google Scholar]
  18. Canoso J. J., Cohen A. S. Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum. 1974 Jul-Aug;17(4):383–390. doi: 10.1002/art.1780170407. [DOI] [PubMed] [Google Scholar]
  19. Chang J., Geary C. G. Therapy-linked leukemia. Lancet. 1977 Jan 8;1(8002):97–97. doi: 10.1016/s0140-6736(77)91113-8. [DOI] [PubMed] [Google Scholar]
  20. Chanmougan D., Schwartz R. S. Enhancement of antibody synthesis by 6-mercaptopurine. J Exp Med. 1966 Sep 1;124(3):363–378. doi: 10.1084/jem.124.3.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Cobau C. D., Sheon R. P., Kirsner A. B. Immunosuppressive drugs and acute leukemia. Ann Intern Med. 1973 Jul;79(1):131–132. doi: 10.7326/0003-4819-79-1-131_2. [DOI] [PubMed] [Google Scholar]
  22. Cooperman J. M. Microbiological assay of serum and whole-blood folic acid activity. Am J Clin Nutr. 1967 Sep;20(9):1015–1024. doi: 10.1093/ajcn/20.9.1015. [DOI] [PubMed] [Google Scholar]
  23. Currey H. L., Harris J., Mason R. M., Woodland J., Beveridge T., Roberts C. J., Vere D. W., Dixon A. S., Davies J., Owen-Smith B. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. Br Med J. 1974 Sep 28;3(5934):763–766. doi: 10.1136/bmj.3.5934.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. DUTHIE J. J., BROWN P. E., TRUELOVE L. H., BARAGAR F. D., LAWRIE A. J. COURSE AND PROGNOSIS IN RHEUMATOID ARTHRITIS. A FURTHER REPORT. Ann Rheum Dis. 1964 May;23:193–204. doi: 10.1136/ard.23.3.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dale G. A., Smith R. B. Transitional cell carcinoma of the bladder associated with cyclophosphamide. J Urol. 1974 Nov;112(5):603–604. doi: 10.1016/s0022-5347(17)59806-7. [DOI] [PubMed] [Google Scholar]
  26. Davis P. Undesirable effects of gold salts. J Rheumatol Suppl. 1979;5:18–24. [PubMed] [Google Scholar]
  27. DeBoer K. P., Kleinman R., Teodorescu M. Identification and separation by bacterial adherence of human lymphocytes that suppress natural cytotoxicity. J Immunol. 1981 Jan;126(1):276–281. [PubMed] [Google Scholar]
  28. Deicher H., Fricke R. Untersuchungen zur Therapie der Rheumatoiden Arthritis (progressiven chronischen Polyarthritis) mit Zytostatika. Z Rheumaforsch. 1969 Jan-Feb;28(1):20–29. [PubMed] [Google Scholar]
  29. Denman E. J., Denman A. M., Greenwood B. M., Gall D., Heath R. B. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis. 1970 May;29(3):220–231. doi: 10.1136/ard.29.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Deshayes P., Rénier J. C., Bregeon C., Houdent G. Incidents et accidents des thérapeutiques a visée immunodépressive dans la polyarthrite rhumatoïde. Rev Rhum Mal Osteoartic. 1971 Dec;38(12):797–806. [PubMed] [Google Scholar]
  31. Dixon A. J., Davies J., Dormandy T. L., Hamilton E. B., Holt P. J., Mason R. M., Thompson M., Weber J. C., Zutshi D. W. Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen. Ann Rheum Dis. 1975 Oct;34(5):416–421. doi: 10.1136/ard.34.5.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Dixon A. S., Lindsay D. J., Collins E. M. Immunosuppressive drugs in rheumatoid arthritis. Br Med J. 1971 Feb 20;1(5746):460–460. doi: 10.1136/bmj.1.5746.460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Duclos H., Maillot M. C., Kreis H., Fries D., Galanaud P. Depressed T suppressor cell function in PBL of transplanted patients under azathioprine and corticosteroids. Transplant Proc. 1979 Jun;11(2):1246–1247. [PubMed] [Google Scholar]
  34. Duclos H., Maillot M. C., Kreis H., Galanaud P. T suppressor cell function impairment in peripheral blood lymphocytes from transplant recipients under azathioprine and corticosteroids. Transplantation. 1979 Nov;28(5):437–438. doi: 10.1097/00007890-197911000-00022. [DOI] [PubMed] [Google Scholar]
  35. Dwosh I. L., Stein H. B., Urowitz M. B., Smythe H. A., Hunter T., Ogryzlo M. A. Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum. 1977 Mar;20(2):685–692. doi: 10.1002/art.1780200208. [DOI] [PubMed] [Google Scholar]
  36. Ederer F., Mantel N. Confidence limits on the ratio of two Poisson variables. Am J Epidemiol. 1974 Sep;100(3):165–167. doi: 10.1093/oxfordjournals.aje.a112024. [DOI] [PubMed] [Google Scholar]
  37. Elliott G. B., Silverberg D. S., Dossetor J. B., Muir C. S. Latent carcinoma of the prostate in a 24-year-old man receiving cyclophosphamide and azathioprine. Can Med Assoc J. 1977 Mar 19;116(6):651–652. [PMC free article] [PubMed] [Google Scholar]
  38. FORNI A. M., KOSS L. G., GELLER W. CYTOLOGICAL STUDY OF THE EFFECT OF CYCLOPHOSPHAMIDE ON THE EPITHELIUM OF THE URINARY BLADDER IN MAN. Cancer. 1964 Oct;17:1348–1355. doi: 10.1002/1097-0142(196410)17:10<1348::aid-cncr2820171017>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  39. FREEDMAN A., STEINBERG V. L. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis. 1960 Sep;19:243–250. doi: 10.1136/ard.19.3.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. FRISCH A. W., DAVIES G. H. Inhibition of hemagglutinin formation by thioguanine: dose-time relationships. Proc Soc Exp Biol Med. 1962 Jul;110:444–447. doi: 10.3181/00379727-110-27544. [DOI] [PubMed] [Google Scholar]
  41. Feng P. H., Cheah P. S., Lee Y. K. Mortality in systemic lupus erythematosus: a 10-year review. Br Med J. 1973 Dec 29;4(5895):772–774. doi: 10.1136/bmj.4.5895.772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Fosdick W. M., Parsons J. L., Hill D. F. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum. 1968 Apr;11(2):151–161. doi: 10.1002/art.1780110205. [DOI] [PubMed] [Google Scholar]
  43. Fraser T. N. Gold Treatment in Rheumatoid Arthritis. Ann Rheum Dis. 1945 Jun;4(4):71–75. doi: 10.1136/ard.4.4.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. GOEBEL K. M., Janzen R., Joseph K., Börngen U. Disparity between clinical and immune responses in a controlled trial of azathioprine in rheumatoid arthritis. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):405–410. doi: 10.1007/BF00606556. [DOI] [PubMed] [Google Scholar]
  45. Giblett E. R., Ammann A. J., Wara D. W., Sandman R., Diamond L. K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975 May 3;1(7914):1010–1013. doi: 10.1016/s0140-6736(75)91950-9. [DOI] [PubMed] [Google Scholar]
  46. Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067–1069. doi: 10.1016/s0140-6736(72)92345-8. [DOI] [PubMed] [Google Scholar]
  47. Gilmore I. T., Holden G., Rodan K. S. Acute leukaemia during azathioprine therapy. Postgrad Med J. 1977 Mar;53(617):173–174. doi: 10.1136/pgmj.53.617.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Goldenberg G. J., Paraskevas F., Israels L. G. The association of rheumatoid arthritis with plasma cell and lymphocytic neoplasms. Arthritis Rheum. 1969 Dec;12(6):569–579. doi: 10.1002/art.1780120604. [DOI] [PubMed] [Google Scholar]
  49. Grooten J., De Baetselier P., Vercauteren E., Hamers R. Anti-micrococcus antibodies recognize an antigenic marker of confluent mouse lymphoid cell lines. Nature. 1980 Jun 5;285(5764):401–403. doi: 10.1038/285401a0. [DOI] [PubMed] [Google Scholar]
  50. Gumpel J. M., Hall A., Ansell B. Proceedings: A double-blind comparative trial of cyclophosphamide and gold in rheumatoid arthritis. Ann Rheum Dis. 1974 Nov;33(6):574–574. doi: 10.1136/ard.33.6.574-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Gupta P. K., Pinn V. M., Taft P. D. Cervical dysplasia associated with azathioprine (Imuran) therapy. Acta Cytol. 1969 Jul;13(7):373–376. [PubMed] [Google Scholar]
  52. Gupta S., Good R. A. Markers of human lymphocyte subpopulations in primary immunodeficiency and lymphoproliferative disorders. Semin Hematol. 1980 Jan;17(1):1–29. [PubMed] [Google Scholar]
  53. HAMILTON E. B., SCOTT J. T. Hydroxychloroquine sulfate ("plaguenil") in treatment of rheumatoid arthritis. Arthritis Rheum. 1962 Oct;5:502–512. doi: 10.1002/art.1780050507. [DOI] [PubMed] [Google Scholar]
  54. Harris J., Jessop J. D., Chaput de Saintonge D. M. Further experience with azathioprine in rheumatoid arthritis. Br Med J. 1971 Nov 20;4(5785):463–464. doi: 10.1136/bmj.4.5785.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Hitchings G. H. Symposium on immunosuppressive drugs. Summary and concluding remarks. Fed Proc. 1967 May-Jun;26(3):958–960. [PubMed] [Google Scholar]
  56. Hoover R., Fraumeni J. F., Jr Risk of cancer in renal-transplant recipients. Lancet. 1973 Jul 14;2(7820):55–57. doi: 10.1016/s0140-6736(73)93256-x. [DOI] [PubMed] [Google Scholar]
  57. Hunter T., Urowitz M. B., Gordon D. A., Smythe H. A., Ogryzlo M. A. Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum. 1975 Jan-Feb;18(1):15–20. doi: 10.1002/art.1780180103. [DOI] [PubMed] [Google Scholar]
  58. Husain Z., Runge L. A. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole. J Rheumatol. 1980 Nov-Dec;7(6):825–830. [PubMed] [Google Scholar]
  59. Huskisson E. C., Gibson T. J., Balme H. W., Berry H., Burry H. C., Grahame R., Hart F. D., Henderson D. R., Wojtulewski J. A. Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report. Ann Rheum Dis. 1974 Nov;33(6):532–535. doi: 10.1136/ard.33.6.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Isomäki H. A., Hakulinen T., Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691–696. doi: 10.1016/0021-9681(78)90071-1. [DOI] [PubMed] [Google Scholar]
  61. Isomäki H. A., Mutru O., Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol. 1975;4(4):205–208. doi: 10.3109/03009747509165257. [DOI] [PubMed] [Google Scholar]
  62. JIMENEZ DIAZ C., LOPEZ GARCIA E., MERCHANTE A., PERIANES J. Treatment of rheumatoid arthritis with nitrogen mustard; preliminary report. J Am Med Assoc. 1951 Dec 8;147(15):1418–1419. [PubMed] [Google Scholar]
  63. Jaffe I. A. The effect of penicillamine on the laboratory parameters in rheumatoid arthritis. Arthritis Rheum. 1965 Dec;8(6):1064–1079. doi: 10.1002/art.1780080606. [DOI] [PubMed] [Google Scholar]
  64. Jensen M. K. Chromosome studies in patients treated with azathioprine and amethopterin. Acta Med Scand. 1967 Oct;182(4):445–455. doi: 10.1111/j.0954-6820.1967.tb10869.x. [DOI] [PubMed] [Google Scholar]
  65. Jensen M. K. Effect of azathioprine on the chromosome complement of human bone marrow cells. Int J Cancer. 1970 Jan 15;5(1):147–151. doi: 10.1002/ijc.2910050119. [DOI] [PubMed] [Google Scholar]
  66. Kahn M. F., Arlet J., Bloch-Michel H., Caroit M., Chaouat Y., Renier J. C. Le risque de leucose aiguë après traitement des rhumatismes inflammatoires chroniques et des connectivites par les cytotoxiques à visée immunosuppressive. Résultats d'une enquête rétrospective portant sur 2006 malades traités. Rev Rhum Mal Osteoartic. 1979 Mar;46(3):163–167. [PubMed] [Google Scholar]
  67. Kahn M. F., Arlet J., Bloch-Michel H., Caroit M., Chaouat Y., Renier J. C. Leucémies aiguës après traitement par agents cytotoxiques en rhumatologie. 19 observations chez 2006 patients. Nouv Presse Med. 1979 Apr 14;8(17):1393–1397. [PubMed] [Google Scholar]
  68. Kay A. G. Myelotoxicity of D-penicillamine. Ann Rheum Dis. 1979 Jun;38(3):232–236. doi: 10.1136/ard.38.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Kean W. F., Dwosh I. L., Anastassiades T. P., Ford P. M., Kelly H. G. The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. Arthritis Rheum. 1980 Feb;23(2):158–164. doi: 10.1002/art.1780230205. [DOI] [PubMed] [Google Scholar]
  70. Keitel W. Ergebnisse und Erfahrungen zur immunsuppressiven Therapie der Rheumatoiden Arthritis. Allerg Immunol (Leipz) 1976;22(3):303–305. [PubMed] [Google Scholar]
  71. Kinlen L. J., Sheil A. G., Peto J., Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979 Dec 8;2(6203):1461–1466. doi: 10.1136/bmj.2.6203.1461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Kinsella P. L., Ebringer R. W., Corbett M. Levamisole in rheumatoid arthritis -- a double-blind study. J Rheumatol. 1980 May-Jun;7(3):288–292. [PubMed] [Google Scholar]
  73. Klein J., Juretic A., Baxevanis C. N., Nagy Z. A. The traditional and a new version of the mouse H-2 complex. Nature. 1981 Jun 11;291(5815):455–460. doi: 10.1038/291455a0. [DOI] [PubMed] [Google Scholar]
  74. Klein M. B., Pereira F. A., Kantor I. Kaposi Sarcoma complicating systemic lupus erythematosus treated with immunosuppression. Arch Dermatol. 1974 Oct;110(4):602–604. [PubMed] [Google Scholar]
  75. Kobayakawa T., Louis J., Izui S., Lambert P. H. Autoimmune response to DNA, red blood cells, and thymocyte antigens in association with polyclonal antibody synthesis during experimental African trypanosomiasis. J Immunol. 1979 Jan;122(1):296–301. [PubMed] [Google Scholar]
  76. Larsson E. L. Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol. 1980 Jun;124(6):2828–2833. [PubMed] [Google Scholar]
  77. Lawler S. D., Klouda P. T., Hardisty R. M., Till M. M. The HL-A system in lymphoblastic leukaemia. A study of patients and their families. Br J Haematol. 1971 Nov;21(5):595–605. doi: 10.1111/j.1365-2141.1971.tb02720.x. [DOI] [PubMed] [Google Scholar]
  78. Lawley P. D. DNA as a target of alkylating carcinogens. Br Med Bull. 1980 Jan;36(1):19–24. doi: 10.1093/oxfordjournals.bmb.a071608. [DOI] [PubMed] [Google Scholar]
  79. Lewis P., Hazleman B. L., Hanka R., Roberts S. Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis. 1980 Oct;39(5):457–461. doi: 10.1136/ard.39.5.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Lewis R. B., Castor C. W., Knisley R. E., Bole G. G. Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1976 Nov-Dec;19(6):1256–1260. doi: 10.1002/art.1780190605. [DOI] [PubMed] [Google Scholar]
  81. Lipsmeyer E. A. Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression. Arthritis Rheum. 1972 Mar-Apr;15(2):183–186. doi: 10.1002/art.1780150207. [DOI] [PubMed] [Google Scholar]
  82. Lorenzen I., Brun C., Videbaek A. Treatment of immunologic diseases with cytostatics. Acta Med Scand. 1969 Jun;185(6):501–506. doi: 10.1111/j.0954-6820.1969.tb07375.x. [DOI] [PubMed] [Google Scholar]
  83. Louie S., Schwartz R. S. Immunodeficiency and the pathogenesis of lymphoma and leukemia. Semin Hematol. 1978 Apr;15(2):117–138. [PubMed] [Google Scholar]
  84. Love R. R., Sowa J. M. Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease. Ann Rheum Dis. 1975 Dec;34(6):534–535. doi: 10.1136/ard.34.6.534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Luukkainen R. Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy. Scand J Rheumatol Suppl. 1980;34:1–56. [PubMed] [Google Scholar]
  86. MOORHEAD P. S., NOWELL P. C., MELLMAN W. J., BATTIPS D. M., HUNGERFORD D. A. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res. 1960 Sep;20:613–616. doi: 10.1016/0014-4827(60)90138-5. [DOI] [PubMed] [Google Scholar]
  87. Manny N., Rosenman E., Benbassat J. Hazard of immunosuppressive therapy. Br Med J. 1972 Apr 29;2(5808):291–291. doi: 10.1136/bmj.2.5808.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Martin P. J., Najfeld V., Hansen J. A., Penfold G. K., Jacobson R. J., Fialkow P. J. Involvement of the B-lymphoid system in chronic myelogenous leukaemia. Nature. 1980 Sep 4;287(5777):49–50. doi: 10.1038/287049a0. [DOI] [PubMed] [Google Scholar]
  89. Mason M., Currey H. L., Barnes C. G., Dunne J. F., Hazleman B. L., Strickland I. D. Azathioprine in rheumatoid arthritis. Br Med J. 1969 Feb 15;1(5641):420–422. doi: 10.1136/bmj.1.5641.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. McAdam L., Paulus H. E., Peter J. B. Adenocarcinoma of the lung during azathioprine therapy. Arthritis Rheum. 1974 Jan-Feb;17(1):92–94. doi: 10.1002/art.1780170114. [DOI] [PubMed] [Google Scholar]
  91. McConkey B., Amos R. S., Durham S., Forster P. J., Hubball S., Walsh L. Sulphasalazine in rheumatoid arthritis. Br Med J. 1980 Feb 16;280(6212):442–444. doi: 10.1136/bmj.280.6212.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. McConkey B., Davies P., Crockson R. A., Crockson A. P., Butler M., Constable T. J., Amos R. S. Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis. Ann Rheum Dis. 1979 Apr;38(2):141–144. doi: 10.1136/ard.38.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. McConkey B., Davies P., Crockson R. A., Crockson A. P., Butler M., Constable T. J. Dapsone in rheumatoid arthritis. Rheumatol Rehabil. 1976 Aug;15(3):230–234. doi: 10.1093/rheumatology/15.3.230. [DOI] [PubMed] [Google Scholar]
  94. McCracken J. D. Letter: Additional risk from immunosuppressive therapy for rheumatoid arthritis. Ann Intern Med. 1973 Oct;79(4):611–612. doi: 10.7326/0003-4819-79-4-611. [DOI] [PubMed] [Google Scholar]
  95. Melnyk J., Duffy D. M., Sparkes R. S. Human mitotic and meiotic chromosome damage following in vivo exposure to methotrexate. Clin Genet. 1971;2(1):28–31. doi: 10.1111/j.1399-0004.1971.tb00251.x. [DOI] [PubMed] [Google Scholar]
  96. Menkès C. J., Lévy J. P., Weill B., Delrieu F., Mathiot C., Delbarre F. Leucémie aiguë à mégacaryoblastes. Survenue après traitement immunodépresseur d'une polyarthrite rhumatoïde. Nouv Presse Med. 1975 Nov 22;4(40):2869–2871. [PubMed] [Google Scholar]
  97. Michlmayr G., Günther R., Lederer B., Huber H. Malignes Lymphom nach zweijähriger immunsuppressiver Therapie einer Periarteriitis nodosa. Med Klin. 1973 Feb 9;68(6):180–182. [PubMed] [Google Scholar]
  98. Miller D. G. The association of immune disease and malignant lymphoma. Ann Intern Med. 1967 Mar;66(3):507–521. doi: 10.7326/0003-4819-66-3-507. [DOI] [PubMed] [Google Scholar]
  99. Moens C., Brocteur J. Treatment of rheumatoid arthritis with immunosuppressive drugs. I. Clinical study. Acta Rheumatol Scand. 1965;11(3):212–220. doi: 10.3109/rhe1.1965.11.issue-1-4.25. [DOI] [PubMed] [Google Scholar]
  100. Moesmann G. Malignancy and mortality in subacute rheumatoid arthritis in old age. Acta Rheumatol Scand. 1969;15(3):193–199. doi: 10.3109/rhe1.1969.15.issue-1-4.28. [DOI] [PubMed] [Google Scholar]
  101. Monson R. R., Hall A. P. Mortality among arthritics. J Chronic Dis. 1976 Jul;29(7):459–467. doi: 10.1016/0021-9681(76)90086-2. [DOI] [PubMed] [Google Scholar]
  102. Mutru O., Koota K., Isomäki H. Causes of death in autopsied RA patients. Scand J Rheumatol. 1976;5(4):239–240. doi: 10.3109/03009747609099912. [DOI] [PubMed] [Google Scholar]
  103. Neuberg R. Immunosuppression and plasmocytoma of the cervix. J Obstet Gynaecol Br Commonw. 1974 Feb;81(2):165–167. doi: 10.1111/j.1471-0528.1974.tb00438.x. [DOI] [PubMed] [Google Scholar]
  104. Nies K., Boyer R., Stevens R., Louie J. Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. Arthritis Rheum. 1980 Dec;23(12):1343–1350. doi: 10.1002/art.1780231203. [DOI] [PubMed] [Google Scholar]
  105. Oleinick A. Leukemia or lymphoma occurring subsequent to an autoimmune disease. Blood. 1967 Jan;29(1):144–153. [PubMed] [Google Scholar]
  106. PLOTZ C. M., SINGER J. M. The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis. Am J Med. 1956 Dec;21(6):888–892. [PubMed] [Google Scholar]
  107. POPERT A. J., MEIJERS K. A., SHARP J., BIER F. Chloroquine diphosphate in rheumatoid arthritis. A controlled trial. Ann Rheum Dis. 1961 Mar;20:18–35. doi: 10.1136/ard.20.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Parker D., Dwyer J. M., Turk J. L. The effect of cyclophosphamide and role suppressor cells in the desensitization of delayed hypersensitivity. Immunology. 1981 May;43(1):191–196. [PMC free article] [PubMed] [Google Scholar]
  109. Patterson J. F., Norton R. A., Schwartz R. S. Azathioprine treatment of ulcerative colitis, granulomatous colitis and regional enteritis. Am J Dig Dis. 1971 Apr;16(4):327–332. doi: 10.1007/BF02235208. [DOI] [PubMed] [Google Scholar]
  110. Pelton B. K., Duncan I. B., Denman A. M. Herpes simplex virus depresses antibody production by affecting T-cell function. Nature. 1980 Mar 13;284(5752):176–177. doi: 10.1038/284176a0. [DOI] [PubMed] [Google Scholar]
  111. Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery. 1978 May;83(5):492–502. [PubMed] [Google Scholar]
  112. Penn I., Starzl T. E. A summary of the status of de novo cancer in transplant recipients. Transplant Proc. 1972 Dec;4(4):719–732. [PubMed] [Google Scholar]
  113. Penn I., Starzl T. E. Immunosuppression and cancer. Transplant Proc. 1973 Mar;5(1):943–947. [PMC free article] [PubMed] [Google Scholar]
  114. Pinals R. S. Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. J Rheumatol. 1976 Jun;3(2):140–144. [PubMed] [Google Scholar]
  115. Proceedings of the 42nd annual meeting of the American Rheumatism Association. A section of the Arthritis Foundation. June 1 & 2, 1978. New York City. Abstracts of papers presented. Arthritis Rheum. 1978 Jun;21(5):539–606. doi: 10.1002/art.1780210508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  117. Rabkin R., Thatcher G. N., Diamond L. H., Eales L. The nephrotic syndrome, malignancy and immunosuppression. S Afr Med J. 1973 Apr 14;47(14):605–606. [PubMed] [Google Scholar]
  118. Rasker J. J., Cosh J. A. Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis. 1981 Apr;40(2):115–120. doi: 10.1136/ard.40.2.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Raven J. L., Walker P. L., Barkhan P. Comparison of the radioisotope dilution-coated charcoal method and a microbiological method (L. leichmannii) for measuring vitamin B12 in serum. J Clin Pathol. 1966 Nov;19(6):610–613. doi: 10.1136/jcp.19.6.610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Renier J. C., Bregeon C., Bonnette C., Boasson M., Bernat M., Basle M., Besson J., Wellinger C., Bourgeois B., Teisseire N. Le devenir des sujets atteints de polyarthrite rhumatoïde et traités par les immunodépresseurs entre 1965 et 1973 inclus. Rev Rhum Mal Osteoartic. 1978 Jul-Sep;45(7-9):453–461. [PubMed] [Google Scholar]
  121. Richter J. A., Runge L. A., Pinals R. S., Oates R. P. Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis. J Rheumatol. 1980 Mar-Apr;7(2):153–159. [PubMed] [Google Scholar]
  122. Rosner F., Grünwald H. Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. Am J Med. 1974 Dec;57(6):927–939. doi: 10.1016/0002-9343(74)90171-5. [DOI] [PubMed] [Google Scholar]
  123. Rothermich N. O., Philips V. K., Bergen W., Thomas M. H. Followup study of chrysotherapy. Arthritis Rheum. 1979 Apr;22(4):423–423. doi: 10.1002/art.1780220418. [DOI] [PubMed] [Google Scholar]
  124. Rynes R. I., Krohel G., Falbo A., Reinecke R. D., Wolfe B., Bartholomew L. E. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum. 1979 Aug;22(8):832–836. doi: 10.1002/art.1780220805. [DOI] [PubMed] [Google Scholar]
  125. SCHWARTZ R., DAMESHEK W. Drug-induced immunological tolerance. Nature. 1959 Jun 13;183(4676):1682–1683. doi: 10.1038/1831682a0. [DOI] [PubMed] [Google Scholar]
  126. SCHWARTZ R., EISNER A., DAMESHEK W. The effect of 6-mercaptopurine on primary and secondary immune responses. J Clin Invest. 1959 Aug;38(8):1394–1403. doi: 10.1172/JCI103915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Scharf J., Nahir M., Eidelman S., Jacobs R., Levin D. Carcinoma of the bladder with azathioprine therapy. JAMA. 1977 Jan 10;237(2):152–152. [PubMed] [Google Scholar]
  128. Seabright M. A rapid banding technique for human chromosomes. Lancet. 1971 Oct 30;2(7731):971–972. doi: 10.1016/s0140-6736(71)90287-x. [DOI] [PubMed] [Google Scholar]
  129. Seidenfeld A. M., Smythe H. A., Ogryzlo M. A., Urowitz M. B., Dotten D. A. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol. 1976 Sep;3(3):295–304. [PubMed] [Google Scholar]
  130. Shand F. L. The immunopharmacology of cyclophosphamide. Int J Immunopharmacol. 1979;1(3):165–171. doi: 10.1016/0192-0561(79)90038-9. [DOI] [PubMed] [Google Scholar]
  131. Sharpstone P., Ogg C. S., Cameron J. S. Nephrotic syndrome due to primary renal disease in adults: II. A controlled trial of prednisolone and azathioprine. Br Med J. 1969 May 31;2(5656):535–539. doi: 10.1136/bmj.2.5656.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Silvergleid A. J., Schrier S. L. Acute myelogenous leukemia in two patients treated with azathioprine for nonmalignant diseases. Am J Med. 1974 Dec;57(6):885–888. doi: 10.1016/0002-9343(74)90165-x. [DOI] [PubMed] [Google Scholar]
  133. Skinner M. D., Schwartz R. S. Immunosuppressive therapy. 1. N Engl J Med. 1972 Aug 3;287(5):221–227. doi: 10.1056/NEJM197208032870504. [DOI] [PubMed] [Google Scholar]
  134. Slater A., Whittaker J. A., Fisher D. J. Letter: Reticulum-cell sarcoma and Sjögren's syndrome in a patient treated with azathioprine. N Engl J Med. 1976 Jan 1;294(1):51–51. [PubMed] [Google Scholar]
  135. Spray G. H. Estimation of red cell folate activity. J Clin Pathol. 1969 Mar;22(2):212–216. doi: 10.1136/jcp.22.2.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Srinivasan R., Miller B. L., Paulus H. E. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum. 1979 Feb;22(2):105–110. doi: 10.1002/art.1780220201. [DOI] [PubMed] [Google Scholar]
  137. Swannell A. J., Coomes E. N. Preliminary results of azathioprine treatment in severe rheumatic disease. Ann Phys Med. 1969 Aug;10(3):112–120. doi: 10.1093/rheumatology/10.3.112. [DOI] [PubMed] [Google Scholar]
  138. Swannell A. J., Kersley G. D. Preliminary results with azathioprine treatment in rheumatoid arthritis. Ann Phys Med. 1969 Nov;10(4):163–166. doi: 10.1093/rheumatology/10.4.163. [DOI] [PubMed] [Google Scholar]
  139. Symington G. R., Mackay I. R., Lambert R. P. Cancer and teratogenesis: infrequent occurrence after medical use of immunosuppressive drugs. Aust N Z J Med. 1977 Aug;7(4):368–372. doi: 10.1111/j.1445-5994.1977.tb04397.x. [DOI] [PubMed] [Google Scholar]
  140. TALAL N., BUNIM J. J. THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME. Am J Med. 1964 Apr;36:529–540. doi: 10.1016/0002-9343(64)90101-9. [DOI] [PubMed] [Google Scholar]
  141. TJIO J. H., WHANG J. Chromosome preparations of bone marrow cells without prior in vitro culture or in vivo colchicine administration. Stain Technol. 1962 Jan;37:17–20. doi: 10.3109/10520296209114563. [DOI] [PubMed] [Google Scholar]
  142. Tausch G., Eberl R., Siegmeth W., Sochor H. Langzeittherapie mit Azathioprin bei einer seit Jahren betreuten Patientengruppe mit progressiv chronischer Polyarthritis. Z Rheumaforsch. 1970 May-Jun;29(5):162–167. [PubMed] [Google Scholar]
  143. Thorpe P. Rheumatoid arthritis treated with chlorambucil: a five-year follow-up. Med J Aust. 1976 Aug 7;2(6):197–199. doi: 10.5694/j.1326-5377.1976.tb130106.x. [DOI] [PubMed] [Google Scholar]
  144. Tolchin S. F., Winkelstein A., Rodnan G. P., Pan S. F., Nankin H. R. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1974 Jul-Aug;17(4):375–382. doi: 10.1002/art.1780170406. [DOI] [PubMed] [Google Scholar]
  145. Turnbull A., Almeyda J. Idiopathic thrombocytopenic purpura and Kaposi's sarcoma. Proc R Soc Med. 1970 Jun;63(6):603–605. doi: 10.1177/003591577006300617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Uddin J., Kraus A. S., Kelly H. G. Survivorship and death in rheumatoid arthritis. Arthritis Rheum. 1970 Mar-Apr;13(2):125–130. doi: 10.1002/art.1780130204. [DOI] [PubMed] [Google Scholar]
  147. Ulrich J., Wüthrich R. Multiple sclerosis: reticulum cell sarcoma of the nervous system in a patient treated with immunosuppressive drugs. Eur Neurol. 1974;12(2):65–78. doi: 10.1159/000114606. [DOI] [PubMed] [Google Scholar]
  148. Unger A., Panayi G. S., Lessof M. H. Carcinoembryonic antigen in rheumatic diseases. Rheumatol Rehabil. 1975 Feb;14(1):19–24. doi: 10.1093/rheumatology/14.1.19. [DOI] [PubMed] [Google Scholar]
  149. Unger A., Panayi G. S., Lessof M. H. Carcinoembryonic antigen in rheumatoid arthritis. Lancet. 1974 Apr 27;1(7861):781–783. doi: 10.1016/s0140-6736(74)92845-1. [DOI] [PubMed] [Google Scholar]
  150. Urowitz M. B., Gordon D. A., Smythe H. A., Pruzanski W., Ogryzio M. A. Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum. 1973 May-Jun;16(3):411–418. doi: 10.1002/art.1780160319. [DOI] [PubMed] [Google Scholar]
  151. Urowitz M. B., Gordon D. A., Smythe H. A., Pruzanski W., Ogryzio M. A. Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum. 1973 May-Jun;16(3):411–418. doi: 10.1002/art.1780160319. [DOI] [PubMed] [Google Scholar]
  152. Vandenbroucke J. P., Kok F. J., Matroos A., Dekker E. Rookgewoonten van Nederlandse huisartsen vergeleken met die van de bevolking. Ned Tijdschr Geneeskd. 1981 Jan 3;125(1):4–6. [PubMed] [Google Scholar]
  153. Verhaegen H., De Cock W., De Cree J. The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients. Clin Exp Immunol. 1977 Aug;29(2):311–315. [PMC free article] [PubMed] [Google Scholar]
  154. Veys E. M., Mielants H., Verbruggen G., Dhondt E., Goethals L., Cheroutre L., Buelens H. Levamisole as basic treatment of rheumatoid arthritis: longterm evaluation. J Rheumatol. 1981 Jan-Feb;8(1):45–56. [PubMed] [Google Scholar]
  155. Vormittag W. Zytostatische immunodepressive Therapie, chromosomale Aberrationen und karzinogene Wirkung. Wien Klin Wochenschr. 1974 Feb 8;86(3):69–75. [PubMed] [Google Scholar]
  156. Walder B. K., Robertson M. R., Jeremy D. Skin cancer and immunosuppression. Lancet. 1971 Dec 11;2(7737):1282–1283. doi: 10.1016/s0140-6736(71)90602-7. [DOI] [PubMed] [Google Scholar]
  157. Wall R. L., Clausen K. P. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med. 1975 Aug 7;293(6):271–273. doi: 10.1056/NEJM197508072930604. [DOI] [PubMed] [Google Scholar]
  158. Webley M., Coomes E. N. An assessment of penicillamine therapy in rheumatoid arthritis and the influence of previous gold therapy. J Rheumatol. 1979 Jan-Feb;6(1):20–24. [PubMed] [Google Scholar]
  159. Wegelius O., Skrifvars B., Andersson L. Rheumatoid arthritis terminating in plasmocytoma. Acta Med Scand. 1970 Jan-Feb;187(1-2):133–138. doi: 10.1111/j.0954-6820.1970.tb02920.x. [DOI] [PubMed] [Google Scholar]
  160. Wheeler G. E. Cyclophosphamide-associated leukemia in Wegener's granulomatosis. Ann Intern Med. 1981 Mar;94(3):361–362. doi: 10.7326/0003-4819-94-3-361. [DOI] [PubMed] [Google Scholar]
  161. Williams H. J., Reading J. C., Ward J. R., O'Brien W. M. Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum. 1980 May;23(5):521–527. doi: 10.1002/art.1780230502. [DOI] [PubMed] [Google Scholar]
  162. Wishart J. Reticulosarcoma of vulva complicating azathioprine-treated dermatomyositis. Arch Dermatol. 1973 Oct;108(4):563–564. [PubMed] [Google Scholar]
  163. Worlledge S. M., Brain M. C., Cooper A. C., Hobbs J. R., Dacie J. V. Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia. Proc R Soc Med. 1968 Dec 12;61(12):1312–1315. doi: 10.1177/003591576806101237. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES